Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Anders, Carey K ^a,b   Adamo, Barbara ^b,c   Karginova, Olga ^b   Deal, Allison M ^b,d   Rawal, Sumit ^b,e   Darr, David ^b   Schorzman, Allison ^b,e   Santos, Charlene ^b   Bash, Ryan ^b   Kafri, Tal ^a,b   Carey, Lisa ^a,b   Miller, C Ryan ^a,b   Perou, Charles M ^a,b   Sharpless, Norman ^a,b   Zamboni, William C ^b,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MESSINA   (Italy)

^d The University of North Carolina at Chapel Hill   (United States)

^e University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; VELIPARIB; 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOLUMINESCENCE; BIOSYNTHESIS; BRAIN METASTASIS; BREAST CANCER; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MICROCIRCULATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OVERALL SURVIVAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; NUDE MOUSE; PATHOLOGY; SECONDARY; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALIA; MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MICE; MICE, NUDE; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877027248     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061359     Document Type: Article

References (41)

1. Lin NU, Bellon JR, Winer EP, (2004) CNS metastases in breast cancer. Journal of clinical oncology 22: 3608-3617.
2. Harrell JC, Prat A, Parker JS, Fan C, He X, et al. (2012) Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast cancer research and treatment 132: 523-535.
3. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, et al. (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972-2977.
4. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, et al. (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 113: 2638-2645.
5. Niwińska A, Murawska M, Pogoda K, (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Annals of Oncology 21: 942-948.
6. Ewend MG, Morris DE, Carey LA, Ladha AM, Brem S, (2008) Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. Journal of the National Comprehensive Cancer Network 6: 505-514.
7. Niwińska A, Murawska M, Pogoda K, (2010) Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 116: 4238-4247.
8. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, et al. (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. Journal of clinical oncology 25: 2295-2305.
9. Gerstner ER, Fine RL, (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. Journal of clinical oncology 25: 2306-2312.
10. Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, et al. (2007) Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clinical cancer research 13: 7217-7223.
11. Walsh MD, Hanna SK, Sen JM, Rawal S, Cabral CB, et al. (2012) Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts. Clinical cancer research 18(9): 2591-2602.
12. Siegal T, Horowitz A, Gabizon A, (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. Journal of neurosurgery 83: 1029-1037.
13. Koukourakis M, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, et al. (2000) High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours. British journal of cancer 83: 1281.
14. Sharma US, Sharma A, Chau RI, Straubinger RM, (1997) Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharmaceutical research 14: 992-998.
15. Coombes R, Bliss J, Wils J, Morvan F, Espie M, et al. (1996) Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. Journal of clinical oncology 14: 35-45.
16. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. (2007) ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clinical cancer research 13: 2728-2737.
17. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA, (1994) Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Molecular pharmacology 45: 649-656.
18. Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R, (2001) A Bone-Seeking Clone Exhibits Different Biological Properties from the MDA-MB-231 Parental Human Breast Cancer Cells and a Brain-Seeking Clone In Vivo and In Vitro. Journal of Bone and Mineral Research 16: 1486-1495.
19. Kafri T, Blömer U, Peterson DA, Gage FH, Verma IM, (1997) Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature genetics 17: 314-317.
20. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation 22: 27-55.
21. Hoadley K, Weigman V, Fan C, Sawyer L, He X, et al. (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC genomics 8: 258.
22. Amselem S, Gabizon A, Barenholz Y, (1990) Optimization and upscaling of doxorubicin-containing liposomes for clinical use. Journal of pharmaceutical sciences 79: 1045-1052.
23. Gabizon A, Shiota R, Papahadjopoulos D, (1989) Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. Journal of the National Cancer Institute 81: 1484-1488.
24. Beijnen J, Rosing H, de Vries PA, Underberg W, (1985) Stability of anthracycline antitumour agents in infusion fluids. PDA Journal of Pharmaceutical Science and Technology 39: 220-222.
25. Gabizon AA, Barenholz Y, Bialer M, (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharmaceutical research 10: 703-708.
26. Roberts PJ, Usary J, Darr D, Dillon PM, Pfefferle AD, et al. (2012) Combined PI3K/mTOR and MEK Inhibition Provides Broad Anti-Tumor Activity in Faithful Murine Cancer Models. Clinical cancer research: 5290-5303.
27. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, et al. (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clinical cancer research 16: 5664-5678.
28. Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, et al. (2009) Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clinical cancer research 15: 1466-1472.
29. O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, et al. (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology 15: 440-449.
30. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, et al. (2011) The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice. Molecular cancer therapeutics 10: 2320-2329.
31. Mason KA, Valdecanas D, Hunter NR, Milas L, (2008) INO-1001, a novel inhibitor of poly (ADP-ribose) polymerase, enhances tumor response to doxorubicin. Investigational new drugs 26: 1-5.
32. Park JW, Benz CC, Martin FJ (2004) Future directions of liposome-and immunoliposome-based cancer therapeutics. Amsterdam: Elsevier. 196-205.
33. Zamboni WC, (2005) Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clinical cancer research 11: 8230-8234.
34. Zamboni WC, Yoshino K, (2010) Formulation and physiological factors affecting the pharmacokinetics and pharmacodynamics of liposomal anticancer agents. Drug delivery system 25: 58-70.
35. Zamboni WC, Maruca LJ, Strychor S, Zamboni BA, Ramalingam S, et al. (2011) Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. Journal of liposome research 21: 158-165.
36. Lay JC, Alexis NE, Zeman KL, Peden DB, Bennett WD, (2009) In vivo uptake of inhaled particles by airway phagocytes is enhanced in patients with mild asthma compared with normal volunteers. Thorax 64: 313-320.
37. van Rooijen N, van Kesteren-Hendrikx E, (2007) The Liposome-Mediated" Macrophage Suicide" Technique: A Tool to Study and Manipulate Macrophage Activities. Liposome Technology: Interactions of liposomes with the biological milieu 3: 303.
38. Zamboni WC, (2008) Concept and clinical evaluation of carrier-mediated anticancer agents. The oncologist 13: 248-260.
39. Madhankumar AB, Slagle-Webb B, Wang X, Yang QX, Antonetti DA, et al. (2009) Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Molecular cancer therapeutics 8: 648-654.
40. Shroff K, Kokkoli E, (2012) PEGylated Liposomal Doxorubicin Targeted to α5β1-Expressing MDA-MB-231 Breast Cancer Cells. Langmuir 28: 4729-4736.
41. Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, et al. (2009) Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Molecular cancer therapeutics 8: 1589-1595.